Turku PET Centre and Division of Clinical Neurosciences, Turku, University Hospital and University of Turku, Turku, Finland
Department of Pharmacology, Drug, Development and Therapeutics, University of Turku, Turku, Finland
Turku PET Centre, Turku University, Hospital and University of Turku, Turku, Finland
Department of Psychiatry, Turku, University Hospital and University of Turku, Turku, Finland
Division of Clinical Neurosciences and Turku PET Centre, Turku University Hospital and University of Turku, Turku, Finland
Send correspondence and reprint requests to Juho Joutsa, MD, PhD, Turku PET Centre, P.O. Box 52, Turku University Hospital, 20521 Turku, Finland. E-mail: email@example.com.
Supported by the Finnish Alcohol Research Foundation, the Finnish Medical Foundation, the Turku University Central Hospital (EVO-funds), the Turku University Foundation, and the Paulo Foundation. Dr Joutsa has received lecturer honoraria from Boehringer-Ingelheim and a research grant from Lundbeck. Dr Hirvonen works currently for Genzyme and has received a research grant from the Orion-Farmos Research Foundation. Dr Hietala has received speaker bureau honoraria and/or travel funds from Janssen, Bristol-Myers, Lilly, Astra-Zeneca, Pfizer and Lundbeck; served as a member of the advisory board of Servier and acts as a consultant for Orion-Pharma. Dr Kaasinen has received speaker honoraria and/or travel grants from Merck, Medtronic, Orion-Pharma, Abbvie, UCB, and Lundbeck; and has served as a member of the advisory board of UCB and as a consultant for Orion-Pharma and Lundbeck.
The authors declare no conflicts of interest.
Received December 20, 2013
Accepted February 26, 2014